Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$20.50 ▼ -0.06
(-0.29%)
MKT CAP: $400.8M • VOL: 139.6K
52W L $16 52W H $40
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
TECX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$84.0M | -$58.0M | -$44.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$74.15B | -$57.98B | -$42.82B |
| EBITDA (Normalized) | -$83.9M | -$57.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$60.1M | -$59.1M | -$40.7M |
| Capital Expenditures (CapEx) | $208.0K | $156.0K | — |
| Free Cash Flow (FCF) | -$60.3M | -$59.2M | -$40.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $253.8M | $141.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $251.3M | $140.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TECX.